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Inhaler Devices of Corticosteroid
Preparations
Gen Tamura1, Hirokazu Sakae2 and Satoshi Fujino2
ABSTRACT
Background: Although investigations of the drug aerosols generated from inhaled corticosteroid (ICS) prepa-
rations and combined drug preparations provide basic information about inhalation therapy, many clinicians
have one-sided data about the precision of drug aerosols from the manufacturer. The present study was con-
ducted to analyze and compare the performances of dry powder inhaler (DPI) devices of ICS and combined
drug preparations.
Methods: The particle size of individual aerosols was measured according to the time-of-flight principle in
terms of their aerodynamic diameter by using the aerodynamic particle sizer spectrometer Model 3321. Percent
aerosolization was measured using only stage #0 and backup filters of the Andersen non-viable sampler model
AN-200.
Results: The particle size distribution of aerosols generated from a TurbuhalerTM and TwisthalerTM showed a
mono-modal distribution of less than 5 μm. In contrast, DiskusTM showed a polydisperse distribution, ranging
from 0.5 to 20 μm. The percentages of DPI preparations converted into aerosols with a particle size less than
11 μm at a suction flow rate of 28.3 Lmin were 5.7-6.2% for Diskus, 37.5-47.0% for Turbuhaler, and 19.8% for
Twisthaler. At a suction flow rate of 60 Lmin, the conversion percentages for DPI preparations into aerosols
with a particle size less than 7.6 μm were 5.9-7.5%, 78.2-86.7%, and 43.5%, respectively.
Conclusions: Because in vitro differences in the aerosolization among different DPI devices containing ICS
and combined drug preparations were observed, prescribers of these preparations should consider whether the
patients will benefit more from the treatment of the central airways versus the peripheral airways.
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ABBREVIATIONS
APS, aerodynamic particle sizer; BFC, combination of BUD and formoterol; BUD, budesonide; DPI, dry powder
inhaler; FP, fluticasone; ICS, Inhaled corticosteroid; MF, mometasone furoate; MMAD, mass median aerody-
namic diameter; SFC, combination of FP and salmeterol xinafoate.
INTRODUCTION
Inhaled corticosteroid (ICS) and a combination of
ICS and a long-acting β2 stimulant (LABA) are used
as first-line drugs for the long-term management of
asthmatic patients. At present in Japan, the ICS prepa-
rations available for application with a dry powder in-
haler (DPI) are fluticasone propionate (FP)-DPI,
budesonide (BUD)-DPI, and mometasone furoate
(MF)-DPI. In addition to these preparations, the com-
bination of FP and salmeterol xinafoate (SFC)-DPI
and that of BUD and formoterol (BFC)-DPI are avail-
able. Although the anti-asthmatic effects of these
preparations have been evaluated in premarketing
clinical trials, detailed data on the performances of
devices for DPI preparations are limited.
We have previously reported in Japan1 the precise
distribution of the particle size of aerosols generated
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Fig.　1　Flow line for measurement of particle size.
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from some devices as well as large differences in the
percentage of aerosolization between certain devices
for DPI preparations. However, there are very few re-
ports comparing the performance of several devices
using the same method.2,3 As well with the recent in-
troduction in Japan of MF-DPI and BFC-DPI, there is
little data available on these new preparations. The
present study was undertaken to analyze and com-
pare the performance of the main devices for 5 DPI
preparations (FP-DPI, BUD-DPI, MF-DPI, SFC-DPI,
and BFC-DPI). The devices tested were Diskus for
FP-DPI and SFC-DPI, Turbuhaler for BUD-DPI and
BFC-DPI, and Twisthaler for MF-DPI.
METHODS
AEROSOL SAMPLING
Figure 1 shows the flow line for measurements of the
particle size of the drug aerosol. In the present study,
we used 60 Lmin, which is the mean inhalation flow
rate for asthmatic patients,4 and 30 Lmin at the suc-
tion flow rates, because some patients who have low
inspiratory flow cannot inhaled DPI preparations. Be-
cause the sample flow rate of the aerodynamic parti-
cle sizer (APS) spectrometer Model 3321 (TSI Incor-
porated, MN, USA) is fixed at 5 Lmin, we set the tar-
get suction flow rates (30 and 60 Lmin) with an aux-
iliary suction pump combined with a glass flow di-
vider. The apparatus was regularly calibrated using
STADEX SC-103 S (JSR Corporation, Tokyo, Japan).
All experiments were performed under steady flow
through the glass flow divider at each suction flow
rate. For all devices, to generate aerosols by wedging
the device inlet into the inlet of the glass flow divider,
a carbon-mixed silicone tube was attached to the
glass flow divider inlet. This tube can be made elec-
troconductive to minimize aerosol particle attach-
ment. Before the start of the measurement, it was
confirmed that this electroconductive tube was
wedged in a reliable manner into the inlet of each de-
vice. Because the maximum concentration compat-
ible with the APS spectrometer was 1,000 particles
mL, the sample concentration was diluted 1 : 10 with
a diluter. When actually analyzed, a considerable
amount of coarse aggregates of powder hit the throat
area of the glass tube, resulting in sedimentation
within the flow divider. Thus, the measurement of the
particle size of the drug aerosol with the APS spec-
trometer was only possible for the fine-aerosolized
part in the case of DPI preparations.
PARTICLE SIZE MEASUREMENT
Within the APS spectrometer, the particle size of
each individual aerosol is measured as an aerody-
namic diameter using a time-of-flight principle. A spe-
cial acuate nozzle with a very small inner diameter is
fitted at the inner side of the sample line tip, and sam-
ple particles are accelerated during passage through
this nozzle. The sample particles accelerated with
this nozzle are carried to the detector unit, where
they pass through 2 laser beams. The time needed
for 1 sample particle to pass through 2 laser beams
(time-of-flight) is analyzed every 4 nanoseconds, al-
lowing high temporal resolution. Thus, since this
transit time depends on the particle size, the APS
spectrometer is designed to conduct a real-time
measurement of the distribution of the particle size as
Performance of Devices for DPI
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Fig.　2　Flow line for measurement of the percentage of aerosolization.
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Fig.　3　Distribution of the particle size of aerosols generated from devices for dry 
powder inhaler of inhaled corticosteroid. The mass concentration for each particle 
size channel (Y-axis) is shown as a percentage relative to the sum total of the 
mass concentration for aerosols of each drug (100%) at an inhalation fl ow rate of 
30 L/min.
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aerodynamic diameter by measuring the time needed
for passage of individual sample particles.
The APS spectrometer Model 3321 is capable of
measuring particle sizes between 0.5 and 20 μm in
terms of aerodynamic diameter and yields data in
units of particle number per mL. Because it is de-
signed to conduct evaluations on the basis of the spe-
cific gravity at 1 gmL of equivalent aerodynamic di-
ameter, the volume is determined with a computer
program from the aerodynamic diameter measured
with the APS spectrometer, followed by conversion of
the specific gravity and particle number into mass.
For comparison of the data from a number of drug
preparations, the sum total of mass of drug aerosols
was deemed as 100%, and the mass of each particle
size channel was expressed as percentage relative to
the sum total, followed by graphic representation of
the frequency distribution and cumulative mass dis-
tribution. The coefficient of variation in our measure-
ment of MMAD was 2.84%. Therefore, our method
employed for measurement of MMAD is highly re-
producible.
MEASUREMENT OF PERCENT AEROSOLIZA-
TION
Since, during the actual measurement of the devices,
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Fig.　4　Distribution of the particle size of aerosols generated from devices for dry 
powder inhaler of combined drug. The mass concentration for each particle size 
channel (Y-axis) is the same in Figure 3.
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Table　1　Mass median aerodynamic diameter for each 
preparation of inhaled corticosteroid at suction fl ow rates of 
30 and 60 L/min
Devices
Suction fl ow rate
30 L/min
MMAD
(μm)
60 L/min
MMAD
(μm)
FP-DPI (Diskus) 3.63 3.58
BUD-DPI (Turbuhaler) 2.29 2.04
MF-DPI (Twisthaler) 2.31 2.51
SFC-DPI (Diskus) 3.55 3.34
BFC-DPI (Turbuhaler) 2.36 2.20
The values of MMAD for each device at each suction fl ow rate 
are averages of the values measured in 6 tests.
Table　2　Percentage of aerosolization of DPI preparations 
at inhalation fl ow rates of 28.3 and 60 L/min
Devices
Suction fl ow rate
28.3 L/min
(<11 μm)
60 L/min
(<7.6 μm)
FP-DPI (Diskus) 6.2% 5.9%
BUD-DPI (Turbuhaler) 47.0% 78.2%
MF-DPI (Twisthaler) 19.8% 43.5%
SFC-DPI (Diskus) 5.7% 7.5%
BFC-DPI (Turbuhaler) 37.5% 86.7%
coarse aggregates of powder were found at the throat
and the bottom of the flow divider, the percentage of
the drug aerosolized by each device was measured
using only stage #0 and backup filters of the An-
dersen non-viable sampler model AN-200 (Tokyo
Dylec Corp, Tokyo, Japan). As shown in Figure 2, the
sample was introduced via a 20-cm long straight elec-
troconductive tube with no obstacles such as the flow
divider. The collection plate of the stage #0 filter is ca-
pable of capturing aerosols over 11 μm in size at a
suction flow rate of 28.3 Lmin and over 7.6 μm at a
suction flow rate of 60 Lmin. In view of the possibil-
ity that once the particles hit the collection plate of
the stage #0 filter they are dispersed again without
being captured, we used a stainless steel coated the
surface with grease as a capturing collection plate.
RESULTS
AEROSOL PARTICLE SIZE
The particle size distribution of aerosols generated
from each device for a mass aerodynamic diameter
range of 0.5-20 μm is shown in Figure 3 for ICS prepa-
rations and Figure 4 for combined drug preparations
at a suction flow rate of 30 Lmin. A similar distribu-
tion of aerosol particle size is shown for an inhalation
flow rate of 60 Lmin. As shown in Figure 3, a mono-
modal distribution less than 5 μm peaking at approxi-
mately 2 μm was recorded with the Turbuhaler with
BUD-DPI and the Twisthaler with MF-DPI. In con-
trast, the Diskus with FP-DPI showed a polydisperse
distribution, ranging from 0.5 to 20 μm and peaking
at approximately 3 μm. As shown in Figure 4, the par-
ticle size of aerosols produced by both the Turbu-
haler and Diskus devices had almost similar distribu-
tions regardless of the type of drug that they con-
tained. The mass median aerodynamic diameter
(MMAD) at 2 different suction flow rates are shown
in Table 1. With the exception of the Twisthaler for
MF-DPI, the Diskus and Turbuhaler tended to have a
smaller MMAD as the suction flow rate increased.
PERCENTAGE AEROSOLIZATION
As shown in Table 2, the percentages of DPI prepara-
tions converted into aerosols with a particle size less
Performance of Devices for DPI
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than 11 μm at a suction flow rate of 28.3 Lmin were
5.7-6.2% using the Diskus, 37.5-47.0% using the Tur-
buhaler, and 19.8% using the Twisthaler. At a suction
flow rate of 60 Lmin, the conversion of the DPI
preparations into aerosols with a particle size less
than 7.6 μm were 5.9-7.5% with the Diskus, 78.2-86.7%
with the Turbuhaler, and 43.5% with the Twisthaler.
DISCUSSION
Using the APS spectrometer Model 3321,5,6 we evalu-
ated the performance of the main devices used for
DPI, namely Diskus, Turbuhaler, and Twisthaler.
Typically, cascade impactors are most frequently
used for measuring the MMAD of these devices. Al-
though cascade impactors are relative inexpensive
aerodynamic sizing instruments, the precision of cas-
cade impactor measurements is limited due to the
fact that the stage collection efficiency curves of im-
pactors are not perfectly sharp7,8 and because of
manufacturing tolerances.9,10 In addition, the APS
spectrometer Model 3321 allows for accurate size dis-
tribution measurements to be made in minutes as op-
posed to the hours required to conduct and analyze
size distribution measurements from cascade impac-
tors.5 As a result, we gained continuous distribution
of the particle size of aerosols generated from these
devices.
An advantage of DPI preparations is that since the
drug supplied in this form is aerosolized only by the
patient’s own inspiratory power, no extra energy is
needed for aerosolization. Accordingly, these prepa-
rations are unlikely to cause environmental damage.
A shortcoming of DPI preparations, however, is that
they cannot be inhaled by some patients who have
low inspiratory flow. Therefore, in the present study,
we used 60 Lmin, which is the mean inhalation flow
rate for asthmatic patients,4 and 30 Lmin at the suc-
tion flow rates.
As shown in Table 1, even at a suction flow rate of
30 Lmin, the MMADs of these devices were be-
tween 2.29 and 3.63 μm, which are suitable for move-
ment and deposition in the central airway.11 As
shown in Figures 3 and 4, a mono-modal distribution
of aerosol particle size less than 5 μm was recorded
with the Turbuhaler and Twisthaler. Therefore, fine
aerosol particles of BUD-DPI and MF-DPI may move
and deposit from the central airway to the parenchy-
mal lungs. Diskus showed a polydisperse distribu-
tion, ranging from 0.5 to 20 μm. Although the sites of
lung deposition of the 2.7 and 3.6 μm aerosols of
MMAD were similar,12 aerosols particles more than 6
μm generated from the Diskus may not reach the
central airway.
For Diskus, the percentage of the drug converted
into aerosols with a particle size of less than 10 μm
was calculated to be only 5.7-7.9% of the bulk formula-
tion delivered. This could be because of the high
amount of lactose in the formulation. Actually, some
reports13,14 have suggested that FP rather than lac-
tose undergoes aerosolization, however those analy-
sis were based on the Electronic LungTM, which has
a large, 11 L space,15 the “sampling chamber”, be-
tween the inhalation device and the cascade impac-
tor. In addition, the systemic availability of fluticasone
via Diskus has been reported to be about 13%.16
Therefore, without the Electronic Lung, it is impor-
tant that the manufacturer should disclose what per-
cent of actual drugs is included in fine aerosol parti-
cles less than 5 μm. This information will help to safe-
guard the patients against local adverse reactions
such as hoarseness and oral candidiasis.
For Turbuhaler for BUD-DPI and Twisthaler for
MF-DPI, at a suction flow rate of 60 lmin, the per-
centage of aerosols with a particle size of 0.8-5 μm
was calculated to be 73.9% and 40.0%, respectively. Al-
though we could not conclude whether this differ-
ence was due to the blend ratio of anhydro-lactose in
the agglomerate, these devices are expected to facili-
tate the delivery and deposition of aerosols in an ex-
tensive area of the central and peripheral airways.
However, even when the percentage of aerosolization
is high, the drug will not exert anti-inflammatory ac-
tion in the peripheral airways unless the inspired air
reaches the airways. It is essential that the patients
using these devices inspire deeply after deep expira-
tion, because deep expiration does not block inhala-
tion of agents.17 In addition, since an increase in the
inhalation flow rate elevates the percentage of aero-
solization, it is necessary to instruct the patient to in-
spire forcefully.
In the present study, we have displayed in vitro dif-
ferences in the aerosolization among different de-
vices for DPI of ICS and combined drug preparations.
Prescribers of these preparations should consider
whether the patients will benefit more from the treat-
ment of the central airways versus the peripheral air-
ways. In addition, attention should also be paid to the
performance of the inhalation technique planned for
use.
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